Overweight not only contributes to the development of type 2 dm but it is the main factor in the incorrect control of the same too.
Endobarrier is a new non-surgical option, which has proved, in clinical research, to help patients acquire greater control over their DMT2 and to lose weight without any changes to the patient’s anatomy.
The EndoBarrier is an endoprosthesic placed in the first 60 cm of the intestine forming a physical barrier between food and a portion of the wall of the intestine. This allows the food to quickly reach the other end of the intestine without being digested, enabling weight loss and improving insulin production by the pancreas, contributing to the control of type 2 diabetes.
This is recommended for patients with a BMI of between 31 and 37, and particularly for those patients who have developed type 2 diabetes and are overweight.
Differently to other metabolic surgery procedures, the EndoBarrier does not modify the patient’s anatomy permanently and it is designed to be removed at the end of the treatment, usually 12 months.